On the 27th, Lin BioScience announced that its new drug LBS-007, developed to treat acute myeloid leukemia (AML), has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). This makes Lin BioScience the first Taiwanese pharmaceutical company to obtain Fast Track Designation for acute leukemia, a milestone that is expected to expedite the drug's path to market and position it to capture a share of the global market, projected to reach USD 7.1 billion by 2030.
Lin BioScience has been making significant strides in drug development. Prior to this, LBS-007 had already received Orphan Drug Designations from the FDA for treating both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The new Fast Track Designation further underscores the FDA's recognition of LBS-007’s novel mechanism of action and promising clinical data, and it is anticipated to accelerate the drug’s regulatory approval and market entry.
Fast Track Designation is an FDA program designed to speed up the development and review process for drugs that demonstrate potential to address serious or life-threatening conditions and meet unmet medical needs. This designation is based on preclinical and clinical data submitted in the application.
With Fast Track Designation, LBS-007 will benefit from more frequent meetings and communications with the FDA. If it meets additional regulatory criteria, the drug may also qualify for Accelerated Approval and Priority Review. Moreover, the program allows for Rolling Review, enabling the submission of New Drug Application (NDA) materials in stages during the Phase III clinical trial, which can significantly expedite the overall review process and potentially bring the drug to market sooner.
Current treatments for acute leukemia primarily rely on chemotherapy, which often comes with severe side effects, high relapse rates, and the development of drug resistance, imposing a heavy burden on patients. Despite this, there are no widely applicable targeted therapies available to date.
LBS-007 is currently undergoing Phase I/II clinical trials in Australia, Taiwan, and the United States, focusing on patients with drug-resistant leukemia who have exhausted treatment options. These patients typically have an average survival time of only 3 to 6 months. Trial progress has been smooth so far, offering hope for this critical patient population.
According to a report by 360iResearch, the combined global market for AML and ALL treatments is projected to reach USD 7.1 billion by 2030, highlighting the immense opportunity for LBS-007 to address unmet medical needs in leukemia treatment.
Resource: 新藥開發報捷！仁新LBS-007獲美國FDA授予快速審查認定
